Skip to main
MSLE

MSLE Stock Forecast & Price Target

MSLE Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Satellos Bioscience is a promising company with a strong financial position, reporting no revenue in 1Q26 but with a reported net loss of only $0.53 per share compared to the consensus estimated net loss of $0.68 per share. Additionally, the company's cash and cash equivalents and short-term investments of approximately $69.9M are expected to fund planned operations through 2027, providing a secure base for their drug development program and potential future success. These financials, combined with their focus on developing a novel therapeutic drug for Duchenne muscular dystrophy, make Satellos Bioscience an attractive investment opportunity with potential for growth in the long term.

Bears say

Satellos Bioscience is a relatively new and small company with limited financial resources, making it a risky investment. The company's main program is focused on a single drug for Duchenne muscular dystrophy, leaving them vulnerable to setbacks and competition from larger biotech companies with more diverse pipelines. Additionally, the company has yet to generate significant revenue and its cost of sales is expected to remain high as they continue with drug development efforts.

MSLE has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Satellos Bioscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Satellos Bioscience Inc (MSLE) Forecast

Analysts have given MSLE a Strong Buy based on their latest research and market trends.

According to 3 analysts, MSLE has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Satellos Bioscience Inc (MSLE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.